The estimated Net Worth of David Lamadrid is at least $7.84 Million dollars as of 6 September 2011. David Lamadrid owns over 12,500 units of Cytosorbents Corp stock worth over $7,837,500 and over the last 15 years David sold CTSO stock worth over $2,750.
David has made over 1 trades of the Cytosorbents Corp stock since 2011, according to the Form 4 filled with the SEC. Most recently David sold 12,500 units of CTSO stock worth $2,750 on 6 September 2011.
The largest trade David's ever made was selling 12,500 units of Cytosorbents Corp stock on 6 September 2011 worth over $2,750. On average, David trades about 6,250 units every 0 days since 2010. As of 6 September 2011 David still owns at least 7,837,500 units of Cytosorbents Corp stock.
You can see the complete history of David Lamadrid stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION, NJ, 08852.
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus, and Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
Cytosorbents Corp executives and other stock owners filed with the SEC include: